These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33327998)

  • 1. [Clinical significance of minimal residual disease in B-lineage acute lymphoblastic leukemia pediatric patients with different fusion gene backgrounds].
    Wei T; Chen XJ; Zhang LY; Zhang AL; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2020 Dec; 22(12):1279-1285. PubMed ID: 33327998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
    Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
    Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.
    Huang YJ; Kuo MC; Jaing TH; Liu HC; Yeh TC; Chen SH; Lin TL; Yang CP; Wang PN; Sheen JM; Chang TK; Chang CH; Hu SF; Huang TY; Wang SC; Wu KH; Chiou SS; Hsiao CC; Shih LY
    J Mol Diagn; 2021 Oct; 23(10):1373-1379. PubMed ID: 34325057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia.
    Huang YJ; Chen SH; Liu HC; Jaing TH; Yeh TC; Kuo MC; Lin TL; Chen CC; Wang SC; Chang TK; Hsiao CC; Liang DC; Shih LY
    Pathology; 2024 Aug; 56(5):681-687. PubMed ID: 38719770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
    Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
    Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].
    Liu F; Chen XJ; Guo Y; Yang WY; Chen X; Zhang XY; Zhang RR; Ren YY; Zhu XF
    Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):896-902. PubMed ID: 33333691
    [No Abstract]   [Full Text] [Related]  

  • 8. [Correlation of E2a-pbx1 expression level with clinical characteristics and early response to treatment in children with acute lymphoblastic leukemia].
    Gao C; Li ZG; Zhao W; Wu MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):569-73. PubMed ID: 18549631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome and Prognostic Factors for
    Lee JW; Kim SK; Jang PS; Chung NG; Jeong DC; Kim M; Cho B; Kim HK
    Cancer Res Treat; 2017 Apr; 49(2):446-453. PubMed ID: 27506214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
    Huang XT; Wang CJ; Gao C; Xue TL; Zhao ZJ; Wang TY; Wu MY; Cui L; Zhang RD; Li ZG
    Ann Hematol; 2024 Sep; 103(9):3657-3665. PubMed ID: 38494553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
    Hoffmann J; Krumbholz M; Gutiérrez HP; Fillies M; Szymansky A; Bleckmann K; Zur Stadt U; Köhler R; Kuiper RP; Horstmann M; von Stackelberg A; Eckert C; Metzler M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27780. PubMed ID: 31034759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
    Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and prognosis of ETV6-RUNX1-positive childhood B-precursor acute lymphocyte leukemia].
    Zheng YZ; Pan LL; Li J; Chen ZS; Hua XL; Le SH; Zheng H; Chen C; Hu JD
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):45-51. PubMed ID: 33677868
    [No Abstract]   [Full Text] [Related]  

  • 16. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
    Wang Y; Zeng HM; Zhang LP
    Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
    Ferrari LC; Rivas MM; Navickas AB; Dick H; Mela Osorio MJ; Agamennoni L; Rey IH; Carnelutto NE; Cazap N; Castro MB; Aranguren PN; Fischman LA; Yupanki ML; Milone JH; Fernández II; Moirano MM; Belli CB;
    Ann Hematol; 2023 May; 102(5):1087-1097. PubMed ID: 36892593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
    Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
    Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring].
    Zhang R; Liao J; Li G; Sun HQ; Shi YJ; Yang JY
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):440-3. PubMed ID: 23791058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.